Alector Assigned 'Hold' Rating by Analysts

Biotech firm faces mixed reviews from Wall Street as it advances Alzheimer's and dementia drug candidates

Mar. 16, 2026 at 8:53am

Got story updates? Submit your updates here. ›

Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies for neurodegenerative disorders, has been assigned an average 'Hold' rating by the eight analysts currently covering the firm, according to MarketBeat Ratings. The analysts' average 12-month price target for Alector's stock is $4.17.

Why it matters

Alector's pipeline of Alzheimer's and frontotemporal dementia drug candidates are closely watched, as the company aims to harness the body's immune system to clear pathological proteins and restore neuronal function. The mixed analyst ratings reflect the challenges and uncertainties facing Alector as it navigates the competitive and high-risk neurodegenerative disease treatment landscape.

The details

The eight analysts covering Alector have issued two 'sell' recommendations, four 'hold' recommendations, and two 'buy' recommendations for the company's stock. Wall Street Zen downgraded Alector from 'hold' to 'sell', while BTIG Research upgraded the stock from 'neutral' to 'buy' with a $6 price target. Morgan Stanley and Weiss Ratings have also maintained 'underweight' or 'sell' ratings on Alector.

  • Alector's stock price opened at $2.20 on Monday, March 16, 2026.
  • The company reported its latest quarterly earnings on Wednesday, February 25, 2026.

The players

Alector, Inc.

A clinical-stage biotechnology company headquartered in South San Francisco, California, focused on developing therapies for neurodegenerative disorders.

Vanguard Group Inc.

A major institutional investor that increased its stake in Alector by 0.8% in the third quarter of 2025, now owning 6,034,659 shares.

683 Capital Management LLC

A hedge fund that boosted its position in Alector by 235% in the fourth quarter of 2025, now owning 3,350,000 shares.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.